Online inquiry

IVTScrip™ mRNA-Anti-IGF1R, 19D12(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ307MR)

This product GTTS-WQ307MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets IGF1R gene. The antibody can be applied in Colon sarcoma research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_000875.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3480
UniProt ID P08069
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IGF1R, 19D12(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ307MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ479MR IVTScrip™ mRNA-Anti-SELP, 42-89-glycoprotein(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA 42-89-glycoprotein
GTTS-WQ3804MR IVTScrip™ mRNA-Anti-NCAM1, BB-10901(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA BB-10901
GTTS-WQ15544MR IVTScrip™ mRNA-Anti-NGcGM3, UNII-52G405U1E5(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA UNII-52G405U1E5
GTTS-WQ4509MR IVTScrip™ mRNA-Anti-CXCL10, BMS-936557(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA BMS-936557
GTTS-WQ11379MR IVTScrip™ mRNA-Anti-IGF, MEDI-573(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA MEDI-573
GTTS-WQ12134MR IVTScrip™ mRNA-Anti-CD248, MORAb-004(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA MORAb-004
GTTS-WQ7257MR IVTScrip™ mRNA-Anti-STAB1, FP-1302(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA FP-1302
GTTS-WQ2694MR IVTScrip™ mRNA-Anti-SOST, AMG 785 (Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA AMG 785
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW